Primary results of the CHIMES study have been published online by the Stroke Journal and will be printed in August’s edition. Researchers found NeuroAiD, a stroke treatment based on Traditional Chinese Medicine, increases the odds of achieving a better functional outcome.
Today we have 40 employees,12 nationalities, and operations throughout several countries.
Advances in research in the field of brain injury, like stroke, trauma and global ischemia, has never been more exciting and encouraging for the prospect of discovering novel effective treatments.
The conventional approach to research in acute treatment to develop one molecule targeted at one specific process in the pathway of one particular disease has failed in many consecutive clinical trials. Moleac takes on a multi-model strategy in its approach to drug development.
Moleac has brought to market the first drug that helps patients recover faster and better from their stroke disabilities.
NeuroAiD™ (MLC 601, MLC 901) addresses these gaps in pharmacological modalities which combined to a rehabilitation program offers new hopes to patients who had no other choice than to cope with their disabilities.